CraniUS Therapeutics

CraniUS Therapeutics is pioneering a novel, implantable drug delivery platform to treat central nervous system disorders. Its flagship NeuroPASS™ device is a fully skull-implantable system that delivers microdoses of therapeutics directly to the brain, bypassing the blood-brain barrier. The technology, currently in pre-clinical development, targets aggressive brain tumors, Alzheimer's, and Parkinson's disease with the goal of improving efficacy and reducing systemic toxicity. Early large animal studies have demonstrated promising results in achieving convective distribution within brain tissue.

NeuroPASS™: A skull-implantable, convection-enhanced drug delivery system designed to bypass the blood-brain barrier by delivering precise microdoses of therapeutics directly into the brain parenchyma. It features MRI-compatibility and a low-profile, invisible design.

Competition includes alternative BBB modulation technologies like focused ultrasound (e.g., Insightec), intranasal delivery platforms, and novel pharmaceutical carriers. Direct competitors in implantable CED devices exist but are few; CraniUS aims to differentiate with its fully implantable, invisible, and MRI-compatible design.